Vanda Pharmaceuticals Inc... (VNDA)

NASDAQ: VNDA · Real-Time Price · USD

4.45

-0.06 (-1.33%)

At close: May 01, 2025, 3:59 PM

4.44

-0.11%

After-hours: May 01, 2025, 04:20 PM EDT

-1.33% (1D)

Bid	4.4
Market Cap	261.96M
Revenue (ttm)	198.77M
Net Income (ttm)	-18.9M
EPS (ttm)	-0.33
PE Ratio (ttm)	-13.47
Forward PE	150.67
Analyst	Strong Buy

Ask	4.47
Volume	290,632
Avg. Volume (20D)	666,673
Open	4.51
Previous Close	4.51
Day's Range	4.42 - 4.52
52-Week Range	3.85 - 6.75
Beta	0.72

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatr...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 12, 2006

Employees 368

Stock Exchange NASDAQ

Ticker Symbol VNDA

Website https://www.vandapharma.com

Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for VNDA stock is "Strong Buy." The 12-month stock price forecast is $20, which is an increase of 349.94% from the latest price.

Stock Forecasts

Next Earnings Release

Vanda Pharmaceuticals Inc. is scheduled to release its earnings on May 12, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

6 months ago

+8.33%

Vanda Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription

10 months ago

-2.84%

Vanda Pharmaceuticals Inc. shares are trading lower after Future Pak withdrew its proposal to purchase the company.

News

2 months ago · seekingalpha.com

Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript

Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Kevin Moran - SVP, CFO & Treasurer Mihael Polymeropoulos - Founder, Presid...

2 months ago · zacks.com

Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.04 per share a year ago.